Form 4: Nektar Therapeutics CEO Sells Shares to Cover Tax Obligations

Nektar Therapeutics CEO, Howard W. Robin, sold a total of 132,030 shares of common stock to cover tax obligations related to vesting RSUs.

Summary

• Nektar Therapeutics CEO, Howard W. Robin, sold 46,995 shares of common stock on December 17, 2024, at a weighted average price of $1.01 per share.
• He then sold an additional 85,035 shares on December 18, 2024, at a weighted average price of $0.99 per share.
• These sales were made to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following these transactions, Mr. Robin directly owns 1,110,675 shares of Nektar Therapeutics common stock and indirectly owns 410 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is neutral, reporting routine stock sales for tax purposes. There is no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• The reported transactions are within the normal range for such activities and do not indicate any unusual behavior compared to similar companies.

Stakeholder Impact

• The stock sales may have a minor impact on the share price, but are not expected to be significant as they are routine transactions.

Key Dates

Keywords

Nektar Therapeutics, Howard W. Robin, stock sale, SEC Form 4, insider trading, RSU, tax obligations